AbbVie (NYSE:ABBV) is navigating significant shareholder activism as it urges opposition to two governance proposals ahead of ...

Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...

Skyrizi (risankizumab ... study called INSPIRE and a 52-week maintenance study called COMMAND. The new use in adults with moderately to severely active UC makes the drug an option for some ...

while Tremfya grew 22% to $2.7 billion from its use in UC, psoriasis, and psoriatic arthritis. Skyrizi meanwhile is making big strides forward, with nine-month 2024 sales up 48% to $7.9 billion ...

The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

This solidified AbbVie's aesthetics and neuroscience presence. Then, it developed the anti-inflammatory drugs Skyrizi and Rinvoq, which are expected to hit $27 billion in sales by 2027 -- well ...

AbbVie’s Skyrizi and Johnson & Johnson’s Tremfya secured fourth and fifth places, generating impressions SOVs of 3.29% and 2.91%, respectively. The brands also achieved 2 billion and 1.8 billion ...